2024 – Atamyo Therapeutics https://atamyo.com Changing life of Neuromuscular patients Tue, 07 Jan 2025 14:03:53 +0000 en-US hourly 1 https://wordpress.org/?v=6.7.4 https://atamyo.com/wp-content/uploads/cropped-favicon_atamyo-1-32x32.png 2024 – Atamyo Therapeutics https://atamyo.com 32 32 An engineered AAV targeting integrin Alpha V Beta 6 presents improved myotropism across species https://atamyo.com/publication/an-engineered-aav-targeting-integrin-alphav-beta-6-presents-improved-myotropism-across-species/ Tue, 07 Jan 2025 14:03:28 +0000 https://atamyo.com/?post_type=publication&p=971 Ai Vu Hong et al., Nature Communications 2024

]]> Preliminary Results from a Phase 1-2 Gene Therapy Study of ATA-100, AAV9 Vector Encoding FKRP, in Patients with Limb Girdle Muscular Dystrophy R9 https://atamyo.com/publication/preliminary-results-from-a-phase-1-2-gene-therapy-study-of-ata-100-aav9-vector-encoding-fkrp-in-patients-with-limb-girdle-muscular-dystrophy-r9/ Mon, 14 Oct 2024 08:40:13 +0000 https://atamyo.com/?post_type=publication&p=896 WMS 2024 Oral Presentation

Sophie Olivier, MD, Chief Medical Officer, Atamyo Therapeutics

]]>